ProCE Banner Activity

My Thoughts on the Evolving Role of Liquid Biopsies in the Treatment of EGFR Mutation–Positive Advanced NSCLC

Clinical Thought
Get up to date on the current and future applications of liquid biopsy in the care of patients with EGFR mutation–positive advanced NSCLC.

Released: June 01, 2021

Expiration: May 31, 2022

Share

Faculty

Christian Rolfo

Christian Rolfo, MD, PhD, MBA, Dr.hc.

Professor of Medicine
Division of Hematology and Oncology
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
Center for Thoracic Oncology
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Christian Rolfo, MD, PhD, MBA, Dr.hc.

Professor of Medicine
Division of Hematology and Oncology
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
Center for Thoracic Oncology
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

Christian Rolfo, MD, PhD, MBA, has disclosed that he has received consulting fees from Archer, Boston Pharmaceuticals, Bristol-Myers Squibb, Inivata, MD Serono, and Novartis; fees for non-CME/CE services from AstraZeneca, MSD, and Roche; funds for research support from Lung Cancer Research Foundation-Pfizer; and non-financial research support from Guardant Health and MD Serono.